NDA 021016 · Upjohn
Relpax
Eletriptan Hydrobromide · Oral
NovelLast checked: Nov 19, 2026Latest source record: Mar 24, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Dec 26, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 1 recruiting
FAERS reports
7,038
3,693 serious, 97 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 15, 2024.
RELPAX is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks. • RELPAX is not intended for the prevention of migraine attacks. • Safety and effectiveness of RELPAX have not been established for cluster headache. RELPAX is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use: • Use only after a clear diagnosis of migraine has been established ( 1 ) • Not indicated for the prophylactic therapy of migraine ( 1 ) • Not indicated for the treatment of cluster headache ( 1 )
Mechanism: Eletriptan binds with high affinity to 5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of RELPAX for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 26, 2002 Original approval · Type 1 - New Molecular Entity NovelLabelReviewOther Important Information from FDA
2 products under this application
- RELPAX · ELETRIPTAN HYDROBROMIDE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- RELPAX · ELETRIPTAN HYDROBROMIDE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Eletriptan Hydrobromide" as an intervention, any sponsor and status, largest first.
Technophage, SAIndustry
NCT06677229 · 28 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 2026
Drug: Eletriptan HBr 40 mg · For: Acute Spinal Cord Injury (SCI)
Sites: Córdoba, Spain; Madrid, Spain
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01139515 · 16 participants · Start Jul 2010 · Primary completion Jul 2010
Drug: Eletriptan commercial tablet; Eletriptan commercial tablet and 2 more · For: Healthy
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective913
- migraine863
- headache733
- nausea502
- pain425
- fatigue335
- vomiting329
- malaise292
- dizziness270
- off label use231
- anxiety223
- feeling abnormal214
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 208 |
| 2005 | 183 |
| 2006 | 112 |
| 2007 | 131 |
| 2008 | 134 |
| 2009 | 75 |
| 2010 | 322 |
| 2011 | 282 |
| 2012 | 451 |
| 2013 | 408 |
| 2014 | 478 |
| 2015 | 618 |
| 2016 | 689 |
| 2017 | 406 |
| 2018 | 392 |
| 2019 | 672 |
| 2020 | 415 |
| 2021 | 244 |
| 2022 | 256 |
| 2023 | 170 |
| 2024 | 177 |
| 2025 | 129 |
| 2026 | 86 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Relpax (Eletriptan Hydrobromide)
2024 spending
$2.8M
Beneficiaries
449
2,201 claims
Per beneficiary
$6,185
$77.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,037,854 |
| 2021 | $3,485,987 |
| 2022 | $3,063,189 |
| 2023 | $3,092,247 |
| 2024 | $2,776,861 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Eletriptan for acute migraine.
Smith LA, Oldman AD, McQuay HJ, et al. · Cochrane Database Syst Rev 2001 · Systematic Review
- WITHDRAWN: Eletriptan for acute migraine.
Smith LA, Oldman AD, McQuay HJ, et al. · Cochrane Database Syst Rev 2007 · Systematic Review
- Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
Kelman L, Von Seggern RL · Am J Ther 2006 · Comparative Study, Meta-Analysis
- Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents.
Sun H, Bastings E, Temeck J, et al. · JAMA Pediatr 2013 · Meta-Analysis, Systematic Review
- Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.
Kim YK, Shin KH, Alderman J, et al. · Drug Des Devel Ther 2018 · Randomized Controlled Trial
- Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo.
Pichard-Garcia L, Hyland R, Baulieu J, et al. · Drug Metab Dispos 2000 · Clinical Trial, Randomized Controlled Trial
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.